Therefore, blocking IL-33 with IL-37, a new inhibitory cytokine, results in an improvement of the low-grade of systemic inflammation, pain, and chronic fatigue syndrome, all symptoms present in pSS [43]. This evidence concerns the gene IL33 and peeling skin syndrome.